Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ONC BeiGene Ltd.
- Stocks
- Healthcare
- NASDAQ: ONC
Price (delayed)
$234.86
Market cap
$25.38B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.29
Enterprise value
$23.86B
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R)
Highlights
The revenue has soared by 51% YoY and by 10% from the previous quarter
The company's gross profit has surged by 51% YoY and by 10% QoQ
BeiGene's quick ratio has increased by 9% QoQ but it has decreased by 5% YoY
Key stats
What are the main financial stats of ONC
Market
Valuations
Earnings
Shares outstanding
108.05M
Market cap
$25.38B
Enterprise value
$23.86B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.17
Price to sales (P/S)
6.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.71
Revenue
$4.18B
Gross profit
$3.54B
Operating income
-$295.75M
Net income
-$392.37M
EBIT
-$306.2M
EBITDA
-$126.93M
Free cash flow
-$175.8M
Per share
Balance sheet
Liquidity
EPS
-$0.29
EPS diluted
-$0.29
Free cash flow per share
-$1.64
Book value per share
$32.76
Revenue per share
$39.01
TBVPS
$54.11
Total assets
$5.84B
Total liabilities
$2.34B
Debt
$996.83M
Equity
$3.5B
Working capital
$1.91B
Debt to equity
0.28
Current ratio
1.96
Quick ratio
1.63
Net debt/EBITDA
11.97
Margins
Efficiency
Dividend
EBITDA margin
-3%
Gross margin
84.8%
Net margin
-9.4%
Operating margin
-7.1%
Return on assets
-6.7%
Return on equity
-11.5%
Return on invested capital
-14%
Return on capital employed
-7.9%
Return on sales
-7.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ONC stock price
How has the BeiGene stock price performed over time
Intraday
-0.46%
1 week
-8.18%
1 month
13.83%
1 year
39.27%
YTD
27.15%
QTD
-13.71%
Financial performance
How have BeiGene's revenue and profit performed over time
Revenue
$4.18B
Gross profit
$3.54B
Operating income
-$295.75M
Net income
-$392.37M
Gross margin
84.8%
Net margin
-9.4%
ONC's operating margin has surged by 82% year-on-year and by 52% since the previous quarter
BeiGene's operating income has surged by 73% YoY and by 48% QoQ
BeiGene's net margin has soared by 67% YoY and by 44% from the previous quarter
The revenue has soared by 51% YoY and by 10% from the previous quarter
Price vs fundamentals
How does ONC's price correlate with its fundamentals
Growth
What is BeiGene's growth rate over time
Valuation
What is BeiGene stock price valuation
P/E
N/A
P/B
7.17
P/S
6.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.71
The company's EPS has surged by 50% YoY and by 38% QoQ
The price to book (P/B) is 26% higher than the 5-year quarterly average of 5.7 and 13% higher than the last 4 quarters average of 6.4
The equity has grown by 5% from the previous quarter and by 4.1% YoY
ONC's price to sales (P/S) is 75% lower than its 5-year quarterly average of 24.5
The revenue has soared by 51% YoY and by 10% from the previous quarter
Efficiency
How efficient is BeiGene business performance
The company's return on sales has surged by 75% YoY and by 52% QoQ
BeiGene's ROIC has soared by 70% YoY and by 49% from the previous quarter
The company's return on assets has surged by 51% YoY and by 40% QoQ
ONC's return on equity is up by 47% year-on-year and by 40% since the previous quarter
Dividends
What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ONC.
Financial health
How did BeiGene financials performed over time
The total assets is 149% greater than the total liabilities
ONC's total liabilities is down by 10% since the previous quarter
BeiGene's quick ratio has increased by 9% QoQ but it has decreased by 5% YoY
BeiGene's debt is 72% less than its equity
BeiGene's debt to equity has decreased by 13% QoQ and by 13% YoY
BeiGene's debt has decreased by 8% from the previous quarter and by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.